血小板减少与脑出血临床结局:回顾性多中心队列研究
该研究基于多中心队列数据,分析血小板减少对脑出血患者血肿扩大、功能结局和死亡率的影响。结果显示血小板减少与血肿扩大及功能结局无关,但在既往抗血小板治疗患者中与3个月死亡率升高相关。
要点
- 血小板减少未显著影响脑出血患者血肿扩大率。
- 血小板减少与3个月功能结局无显著关联。
- 抗血小板治疗合并血小板减少者3个月死亡率更高。
核心结论
- 血小板减少不影响脑出血患者的血肿扩大率和功能结局,无论是否接受抗血小板治疗。
研究设计与样本
- 多中心回顾性队列研究,纳入2252例脑出血患者,其中51.5%使用维生素K拮抗剂。
主要发现
- 抗血小板治疗患者中血肿扩大比例:血小板减少组22.5% vs 非减少组23.5%,P=0.89。
- 非抗血小板治疗患者中血肿扩大比例:血小板减少组31.0% vs 非减少组29.8%,P=0.77。
- 抗血小板治疗患者3个月死亡率:血小板减少组63.0% vs 非减少组41.4%,P=0.01。
- 非抗血小板治疗患者3个月死亡率:血小板减少组41.9% vs 非减少组39.1%,P=0.49。
临床怎么用
- 对于脑出血合并血小板减少患者,不应仅基于血小板计数预测血肿扩大风险。
- 对既往抗血小板治疗的脑出血合并血小板减少患者,需关注死亡率升高风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The impact of platelets on hematoma enlargement (HE) of intracerebral hemorrhage (ICH) is not yet sufficiently elucidated. Especially the role of reduced platelet counts on HE and clinical outcomes is still poorly understood. This study investigated the influence of thrombocytopenia on HE, functional outcome, and mortality in patients with ICH with or without prior antiplatelet therapy (APT). METHODS: Individual participant data of multicenter cohort studies (multicenter RETRACE program [German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage] and single-center UKER-ICH registry [Universitätsklinikum Erlangen Cohort of Patients With Spontaneous ICH]) were grouped into APT and non-APT ICH patients according to the platelet count, that is, with or without thrombocytopenia (cells <150×109/L). Of all patients, 51.5% (1124 of 2183) were on vitamin K antagonist. Imbalances in baseline characteristics including proportions of vitamin K antagonist patients were addressed using propensity score matching. Outcome analyses included HE (>33%), as well as mortality and functional outcome, after 3 months using the modified Rankin Scale, dichotomized into favorable (modified Rankin Scale score, 0-3) and unfavorable (modified Rankin Scale score, 4-6). RESULTS: Of overall 2252 ICH patients, 11.4% (52 of 458) under APT and 14.0% (242 of 1725) without APT presented with thrombocytopenia on admission. The proportion of patients with HE was not significantly different between patients with or without thrombocytopenia among APT and non-APT ICH patients after propensity score matching (HE: APT patients: 9 of 40 [22.5%] thrombocytopenia versus 27 of 115 [23.5%] nonthrombocytopenia, P=0.89; non-APT patients: 54 of 174 [31.0%] thrombocytopenia versus 106 of 356 [29.8%] nonthrombocytopenia, P=0.77). In both (APT and non-APT) propensity score matching cohorts, there were no significant differences regarding functional outcome. Mortality after 3 months did not differ among non-APT patients, whereas the mortality rate was significantly higher for APT patients with thrombocytopenia versus APT patients with normal platelet count (APT: 29 of 46 [63.0%] thrombocytopenia versus 58 of 140 [41.4%] nonthrombocytopenia, P=0.01; non-APT: 95 of 227 [41.9%] thrombocytopenia versus 178 of 455 [39.1%] nonthrombocytopenia, P=0.49). CONCLUSIONS: Our study implies that thrombocytopenia does not affect rates of HE and functional outcome among ICH patients, neither in patients with nor without APT. In light of increased mortality, the significance of platelet transfusions for ICH patients with thrombocytopenia and previous APT should be explored in future studies.
引用
- Mrochen A, Sprügel MI, Gerner ST, et al. Thrombocytopenia and Clinical Outcomes in Intracerebral Hemorrhage: A Retrospective Multicenter Cohort Study. Stroke. 2021. PMID: 33430632. doi:10.1161/STROKEAHA.120.031478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。